Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy with Arthur A.M. Wilde, MD, PhD and Cynthia A. James, ScM, PhD, CGC

• Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders.  

  The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. The webinar presenters will review Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy 2019 consensus statement, recommendations of the expert writing group, and provide clinicians with guidance on evaluation and management of ACM, including clinically relevant information on genetics.

  

  Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.

  

  Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.

Arthur A.M. Wilde, MD, PhD | Presenter

Amsterdam UMC, Academic Medical Center, The Netherlands

Professor Wilde is Head of the Dept. of Clinical and Experimental Cardiology, University of Amsterdam Medical Centre, The Netherlands.

His clinical and research interests include:  the care of patients with arrhythmias, cardiomyopathy, electrophysiology and genetic factors contributing to sudden death.
 
Over his career, he published over 550 scientific papers with a major focus on the different aspects of inherited arrhythmia syndromes.  In 2011, he was appointed as member of the Dutch Academy of Science and in 2012, he received the Heart Rhythm Society Distinguished Investigator award.

Professor Wilde is one of the authors of the consensus statement, Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy, 2019.

Cynthia A. James, ScM, PhD, CGC | Presenter

Johns Hopkins University School of Medicine, Baltimore, Maryland

Dr. Cynthia James is an Assistant Professor of Medicine (Cardiology) and certified genetic counselor at the Johns Hopkins University School of Medicine. Her research focuses on cardiovascular genetic counseling and arrhythmogenic cardiomyopathies. Her team is currently engaged in investigating the interplay of genotype and lifestyle on penetrance and course of ARVD/C as well as improving early detection and risk stratification in ARVD/C.

Dr. James received her undergraduate degree in biology from Cornell University in Ithaca, NY. She earned her Sc.M. in Genetic Counseling at Johns Hopkins School of Public Health and her Ph.D. in Human Genetics at Johns Hopkins University. Dr. James joined the Johns Hopkins faculty in 2013 after a decade as a practicing genetic counselor in the Johns Hopkins ARVD/C program.

Dr. James has been published extensively in the field.  She is one of the authors of the consensus statement, Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy, 2019.

Margo Gallegos, MS, CGC | Moderator

Genomic Science Liaison, Ambry Genetics

Margo Gallegos joined Ambry Genetics in 2020 as the Specialty Genomic Science Liaison for the Northeast United States territory. She previously worked as a pediatric genetic counselor at Children’s National Medical Center in Washington, D.C, and an oncology genetic counselor at Anne Arundel Medical Center in Annapolis, MD. Her volunteer interests include public policy and licensure of genetic counselors both at the state and federal level. Margo received her Bachelors of Science degree in Cell Biology and Genetics from University of Maryland, College Park. She earned her Masters of Science degree in Genetic Counseling from University of South Carolina School of Medicine and is certified by the American Board of Genetic Counseling.